Caldaret

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Caldaret
Accession Number
DB06231
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Caldaret monohydrate2SH110E854192509-24-3ZRQKZWAOIRVBFD-UHFFFAOYSA-N
Categories
UNII
9L3Y3IJ2HI
CAS number
133804-44-1
Weight
Average: 256.32
Monoisotopic: 256.088163557
Chemical Formula
C11H16N2O3S
InChI Key
DCDFLGVJWQIRGH-UHFFFAOYSA-N
InChI
InChI=1S/C11H16N2O3S/c1-9-2-3-10(11(8-9)17(14,15)16)13-6-4-12-5-7-13/h2-3,8,12H,4-7H2,1H3,(H,14,15,16)
IUPAC Name
5-methyl-2-(piperazin-1-yl)benzene-1-sulfonic acid
SMILES
CC1=CC=C(N2CCNCC2)C(=C1)S(O)(=O)=O

Pharmacology

Indication

Investigated for use/treatment in heart disease and myocardial infarction.

Pharmacodynamics
Not Available
Mechanism of action

Cardiac damage due to the buildup of sodium (Na+) ischemia and early reperfusion leads to increased calcium (Ca2+) through the reverse mode Na+/Ca2+(NCX) ion exchanger. Caldaret is an intracardiac calcium (Ca2+) handling modulator whose cardioprotective actions are presumed to be due to inhibition of the NCX exhanger and increasing the uptake of Ca2+ via the sarcoplasmic reticulum (SR).

TargetActionsOrganism
USodium/calcium exchanger 1Not AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
  1. Kawasumi H, Satoh N, Kitada Y: Caldaret, an intracellular Ca2+ handling modulator, limits infarct size of reperfused canine heart. J Pharmacol Sci. 2007 Feb;103(2):222-33. Epub 2007 Feb 14. [PubMed:17299242]
  2. Jang IK, Weissman NJ, Picard MH, Zile MR, Pettigrew V, Shen S, Tatsuno J, Hibberd MG, Tzivoni D, Wackers FJ: A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE). Am Heart J. 2008 Jan;155(1):113.e1-8. Epub 2007 Nov 1. [PubMed:18082500]
External Links
ChemSpider
4938265
ChEMBL
CHEMBL2106572
ZINC
ZINC000001551732

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedPreventionMyocardial Infarction1
2CompletedTreatmentCongestive Heart Failure1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.9 mg/mLALOGPS
logP-1.4ALOGPS
logP0.021ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)-1.7ChemAxon
pKa (Strongest Basic)8.84ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area69.64 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity66.91 m3·mol-1ChemAxon
Polarizability26.02 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Benzenesulfonic acids and derivatives / Benzenesulfonyl compounds / 1-sulfo,2-unsubstituted aromatic compounds / Dialkylarylamines / Aniline and substituted anilines / Aminotoluenes / Sulfonyls / Organosulfonic acids / Dialkylamines
show 4 more
Substituents
Phenylpiperazine / N-arylpiperazine / Benzenesulfonate / Arylsulfonic acid or derivatives / 1-sulfo,2-unsubstituted aromatic compound / Benzenesulfonyl group / Tertiary aliphatic/aromatic amine / Dialkylarylamine / Aniline or substituted anilines / Aminotoluene
show 20 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Ion channel binding
Specific Function
Mediates the exchange of one Ca(2+) ion against three to four Na(+) ions across the cell membrane, and thereby contributes to the regulation of cytoplasmic Ca(2+) levels and Ca(2+)-dependent cellul...
Gene Name
SLC8A1
Uniprot ID
P32418
Uniprot Name
Sodium/calcium exchanger 1
Molecular Weight
108546.06 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on March 19, 2008 10:18 / Updated on March 01, 2020 23:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates